immunotherapy Archives
Discovery points to new cancer immunotherapy option
Feb. 21, 2019—An international team involving Vanderbilt researchers has discovered that a new “checkpoint” protein on immune system cells is active in tumors, and that blocking it — in combination with other treatments — is a successful therapeutic approach in mouse models of cancer.
Breast cancer-killing RIG
Dec. 13, 2018—A compound that activates a virus-sensing receptor has potent therapeutic effects in a mouse model of breast cancer.
Immunotherapies linked to specific heart complications
Nov. 15, 2018—In the first large-scale analysis of cardiovascular complications linked to immune checkpoint inhibitors, Vanderbilt researchers have shown that heart and vessel complications include myocarditis, pericarditis, vasculitis and arrhythmias, and that they occur early in the course of treatment.
Team’s findings show glutamine metabolism affects T cell signaling
Nov. 1, 2018—The cellular nutrient glutamine launches a metabolic signaling pathway that promotes the function of some immune system T cells and suppresses others, Vanderbilt researchers have discovered.
Mary Kay Foundation grant to bolster immunotherapy research
Oct. 25, 2018—An immunotherapy research initiative at Vanderbilt University Medical Center is among those being supported by the Mary Kay Foundation, which has announced $1.2 million in funding that will be equally shared among 12 cancer research institutions.
Study tracks incidence, timing of immunotherapy-related deaths
Sep. 13, 2018—Vanderbilt-Ingram Cancer Center researchers have answered questions about the incidence and timing of rare but sometimes fatal reactions to the most widely prescribed class of immunotherapies.
Cancer immunotherapies expert Allison set for Discovery Lecture
Mar. 1, 2018—James Allison, PhD, whose work led to the development of cancer immunotherapies known as “checkpoint inhibitors,” will deliver the next Flexner Discovery Lecture on Thursday, March 8.
STINGing combination for cancer
Jun. 19, 2017—A novel immunotherapy combination induced remarkable regression of tumors in a mouse model of head and neck cancer.
Richmond to speak at national VA research conference on cancer immunotherapy
May. 11, 2017—Vanderbilt University cancer researcher Ann Richmond, Ph.D., 2016 recipient of one of the highest honors for scientific achievement bestowed by the U.S. Department of Veterans Affairs, will be a keynote speaker during a national VA research conference next week at Vanderbilt University School of Medicine.
Vanderbilt investigator lands Stand Up To Cancer grant for “smart” nanoparticles cancer research
Apr. 3, 2017—John Wilson, Ph.D., assistant professor of Chemical and Biomolecular Engineering and of Biomedical Engineering at Vanderbilt University, has received an Innovative Research Grant from Stand Up To Cancer (SU2C). Wilson is among 10 early-career scientists to receive the grant awards focused on immuno-oncology.
Protecting the blood-brain barrier
Dec. 9, 2016—Vanderbilt investigators have discovered how a promising cancer immunotherapy causes brain swelling, findings that could lead to ways to protect brain function while fighting cancers.
Improving natural killer cancer therapy
Apr. 29, 2016—A newly discovered mechanism that helps cancer cells avoid destruction by immune system cells may improve immunotherapies.
